Literature DB >> 25179741

Mitochondrial substrates in cancer: drivers or passengers?

Björn Kruspig1, Boris Zhivotovsky2, Vladimir Gogvadze3.   

Abstract

The majority of cancers demonstrate various tumor-specific metabolic aberrations, such as increased glycolysis even under aerobic conditions (Warburg effect), whereas mitochondrial metabolic activity and their contribution to cellular energy production are restrained. One of the most important mechanisms for this metabolic switch is the alteration in the abundance, utilization, and localization of various mitochondrial substrates. Numerous lines of evidence connect disturbances in mitochondrial metabolic pathways with tumorigenesis and provide an intriguing rationale for utilizing mitochondria as targets for anti-cancer therapy.
Copyright © 2014 Mitochondria Research Society and Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cell death; Metabolism; Mitochondria; Therapy; Warburg Effect

Mesh：

Substances：

Year:  2014        PMID： 25179741     DOI： 10.1016/j.mito.2014.08.007

Source DB:  PubMed          Journal:  Mitochondrion        ISSN： 1567-7249            Impact factor:   4.160


  10 in total

Review 1.  Pheochromocytoma: The First Metabolic Endocrine Cancer.

Authors:  Ivana Jochmanova; Karel Pacak
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 2.  Pheochromocytoma: Gasping for Air.

Authors:  Ivana Jochmanová; Zhengping Zhuang; Karel Pacak
Journal:  Horm Cancer       Date:  2015-07-03       Impact factor: 3.869

Review 3.  Hitting the Bull's-Eye in Metastatic Cancers-NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death.

Authors:  Stephen John Ralph; Rhys Pritchard; Sara Rodríguez-Enríquez; Rafael Moreno-Sánchez; Raymond Keith Ralph
Journal:  Pharmaceuticals (Basel)       Date:  2015-02-13

Review 4.  Mitochondrial VDAC1: A Key Gatekeeper as Potential Therapeutic Target.

Authors:  Amadou K S Camara; YiFan Zhou; Po-Chao Wen; Emad Tajkhorshid; Wai-Meng Kwok
Journal:  Front Physiol       Date:  2017-06-30       Impact factor: 4.566

5.  Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action.

Authors:  Lewis A Quayle; Maria G Pereira; Gerjan Scheper; Tammy Wiltshire; Ria E Peake; Issam Hussain; Carol A Rea; Timothy E Bates
Journal:  Oncotarget       Date:  2017-09-13

Review 6.  The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.

Authors:  Song Peng; Jun Zhang; Xintao Tan; Yiqiang Huang; Jing Xu; Natalie Silk; Dianzheng Zhang; Qiuli Liu; Jun Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-24       Impact factor: 5.555

7.  The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update.

Authors:  Bruno Bouça; Paula Bogalho; Manfredi Rizzo; José Silva-Nunes
Journal:  Metabolites       Date:  2022-02-01

Review 8.  Oncostatic-Cytoprotective Effect of Melatonin and Other Bioactive Molecules: A Common Target in Mitochondrial Respiration.

Authors:  Nicola Pacini; Fabio Borziani
Journal:  Int J Mol Sci       Date:  2016-03-07       Impact factor: 5.923

Review 9.  Cell death-based treatment of neuroblastoma.

Authors:  Kadri Valter; Boris Zhivotovsky; Vladimir Gogvadze
Journal:  Cell Death Dis       Date:  2018-01-25       Impact factor: 8.469

10.  Expression of MTERF3 gene in breast carcinoma and the relationship with clinicopathological characteristics.

Authors:  Wei-Si Wang; Jia-Ji Zi; Mei-Tao Sun; Wen Mei; Su-Fen Li; Na Yang; Zai-Yi Fei; Ruo-Peng Zhang; Min Yu; Wei Xiong
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.